Arch Awarded Funding from the Government of Canada to Develop Brain Tumour Targeting Technology
TORONTO, CANADA--(Marketwire - March 15, 2012) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that the National Research Council of Canada - Industrial Research Assistance Program (NRC-IRAP) has approved funding up to $107,000 to assist Arch in the development of diagnostic imaging applications for its brain tumour initiating cell ("BTIC") targeting technology.
Arch Scientists to Lead Anti Corrosion Project for Auto Industry
TORONTO, ONTARIO--(Marketwire - Feb. 28, 2012) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that AUTO21 and its contributing partners have approved funding totaling $518,400 for Arch scientists to lead an anti corrosion project on Magnesium ("Mg") and rare earth ("RE") alloys for the Canadian auto industry.
Arch Biopartners Appoints Claude Allary as Special Advisor
TORONTO, ONTARIO--(Marketwire - Jan. 24, 2012) -Arch Biopartners Inc ("Arch" or the "Company") (CNSX:ACH)(OTC:FOIFF) announced today Claude Allary has been appointed Special Advisor to the Company. In this capacity, Mr. Allary will provide expertise in evaluating commercial opportunities for the Company's drug development platforms and other emerging technologies.